Huddart RA, Hall E, Lewis R, et al. - In order to ascertain the effect of treatment on the health-related quality of life (HRQoL) of BC2001 individuals, researchers included a sum of 458 UK individuals with T2-T4a N0 M0 transitional cell carcinoma of the bladder. Individuals were assigned randomly to the chemotherapy comparison (radiotherapy, 178, or chemoradiotherapy, 182); and/or to the radiotherapy comparison (standard, 108, or reduced high-dose volume radiotherapy, 111). They found that HRQoL decreased at EoT, increasing to baseline at 6 months and remaining similar to baseline subsequently. No significant difference was found between randomized groups at any time point. Immediately following (chemo)radiotherapy, they indicated that a significant proportion of individuals report declines in HRQoL, which improve to baseline after 6 months. It was noted that two-thirds of individuals report stable or increased HRQoL on long-term follow-up.